MeSH D054990 - idiopathic pulmonary fibrosis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D011658:Pulmonary fibrosis
D054990:Â
Idiopathic pulmonary fibrosis
D000080203:Hamman-rich syndrome
0 Companies
0 Drugs
Success rate
D054988:Idiopathic interstitial pneumonias
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Axunio | Pirfenidone | Pirfenidone axunio (previously Pirfenidone AET) |  | 2022-06-20 |  |  |
| Boehringer Ingelheim | Nintedanib, Nintedanib esylate | Ofev |  | 2015-01-14 |  |  |
| Nintedanib | Vargatef |  | 2014-11-21 |  |  | |
| Roche | Pirfenidone | Esbriet |  | 2011-02-27 | $749.525 M | Y2022 |
| Viatris | Pirfenidone | Pirfenidone Viatris |  | 2023-01-10 |  |  |
Clinical Trials
Historical Success Rate
Phase 1
63%17/27
Phase 2
35%16/46
Phase 3
27%10/37
Approved: 5Overall Success rate: 6%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use